1Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.Arch Intern Med,1994,154:1449-1457.
2Kannel WB,Abbott RD,Savage DD,et al. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med,1982,306:1018.
5Bogousslavsky J, Van Melle G, Regli F, et al. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology,1990,40:1046-1050.
6Lip GY. Hypercoagulability and haemodynamic abnormalities in atrial fibrillation.Heart,1997,77:395-396.
7Lip GY, Lip PL, Zarifis J, et al. Fibrin D-dimer and betathromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: effects of introducing ultra-low-dose warfarin and aspirin. Circulation,1996,94:425-431.
8Gregorg W, James E, Laupacis A. Antithrombotic therapy in atrial fibrillation. Chest,2001,119:194-206.
9Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med, 1996,335:540-546.
10Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation Ⅲ randomised clinical trial. Lancet, 1996,348:633-638.
